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cant relationships were found between all domains on the
SF-36 with the exception of emotional role limitation and
pain. A regression analysis showed that Hb accounts for
7% of the variability of the fatigue scale of the FACT and
that on this scale a 1 unit rise in Hb equals a rise of 6.27
units. In addition, Hb accounts for an additional 7% of
variability of FACT-An scores and 1 unit rise in Hb
equals a rise of 7.31 units. On average, Hb accounts for
an additional 7% of the variability of the SF-36 scales,
and a 1 unit rise in Hb equals a rise of 7.00 units in SF-36
scales. The PGI showed no relationship with Hb levels.
CONCLUSION: Quality of life as measured by the FACT-
An and the SF-36 is significantly related to Hb levels in
U.K. cancer patients. This indicated that optimization of
patient Hb is likely to increase the quality of life in cancer
patients.
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OBJECTIVE: to estimate the costs and effects of pami-
dronate vs placebo in prevention of bone complications
in metastastic breast cancer in Poland. METHODS: The
model for the Polish health-care context was developed,
based on the use of clinical data from literature and local
data on health-care resource utilization and unit cost.
Only direct medical costs were analyzed. The perspective
of health-care payers and time horizon of 18 months
were taken. In the cost-effectiveness analysis the primary
clinical outcomes for measuring success in the analysis
were the avoided skeletal related events (SRE), which
were defined as pathological fractures, irradiation and
episodes of hypercalcaemia. In the cost-utility analysis
QALY values measured in the analysis were patients
preferences for alternative health outcomes, reported in
the randomized trial. The cost-effectiveness threshold,
calculated on the basis of cost of 1-year haemodialysis
treatment (62 400 PLN, 1 USD  4,5 PLN), was sug-
gested to assess if pamidronate therapy should be adopted.
The one-way sensitivity analysis and threshold analysis
were performed. RESULTS: The costs of avoiding of SRE
for pamidronate vs placebo was 3420 PLN (taking into
consideration lowest costs of treatment of pathological
fractures) or, taking into consideration highest costs of
treatment of pathological fractures, pamidronate treat-
ment was dominant program (129 SRE avoided and 42
546 PLN/100patients/year saved). The cost/QALY gained
was 45 021 PLN or pamidronate was the dominant pro-
gram (9,8 QALY gained and 42 546 PLN/100 patients/
year saved). The results were most sensitive to the costs
of treatment of pathological fractures and number of
SRE avoided. CONCLUSION: Comparing this outcome
with suggested threshold for cost-effectiveness it was
concluded that prophylactic pamidronate therapy for ad-
vanced breast cancer offers substantial benefit at reason-
able cost to the Polish health care system. By assumption
that all pathological fractures would be treated with most
costly methods, pamidronate might be dominant program. 
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Capecitabine is an oral fluoropyrimidine which mimics
continuous 5-FU and is preferentially activated by thymi-
dine phosphorylase to 5-FU within tumor cells. A ran-
domized phase III clinical trial, comparing capecitabine
(n  301, 1250 mg/m2/bid 
 14d, q3 weeks) vs. M-regi-
men (n  301, 5-FU 425 mg/m2; LCV 20 mg/m2 d1-5,
q4 weeks) resulted in a superior response rate (26.6% vs.
17.9%, P  0.013), equivalent progression-free survival
(5.3 vs 4.8 months, HR (hazard ratio) 0.96), equivalent
overall survival (13.2 vs 12.4 months, HR 0.91), and a
superior safety profile for capecitabine. The most remark-
able differences in AEs requiring treatment were lower
rates of infections/sepsis, stomatitis, vomiting, and diar-
rhea and a higher rate of hand-foot syndrome (HFS) for
capecitabine-treated patients. OBJECTIVE: To evaluate
the economic consequences of differences in the AE-pro-
file of capecitabine and M-regimen in colorectal cancer.
METHODS: Patients were recruited from 66 centers in 8
EU-countries, Australia, New Zealand, Russia, Israel and
Taiwan. Data on hospital use, AEs requiring medications
or procedures, and all physician encounters were col-
lected during the clinical trial for all randomized patients
and analyzed. RESULTS: Total days in hospital for: sto-
matitis/mucosal inflammation, HFS, neutropenia, pyr-
exia, infections, diarrhea, nausea and vomiting was re-
duced by 172 hospital days (339 vs. 167, 51%) in the
capecitabine arm. The use of antifungals was reduced by
34% and the usage of 5-HT3-antagonists by 39% in the
capecitabine arm. Although not used frequently, con-
sumption of octreotide and G-CSF was reduced substantially
(100% and 59% respectively) in the capecitabine-treated
group. Overall use of high-cost medication including
cephalosporins and fluoroquinolones was reduced by
56%. Procedures and unscheduled outpatient-visits were
